Research
Hormonal
Unimolecular GIPR:GLP-1R coagonists (e.g., tirzepatide) achieve superior body weight loss compared to GLP-1R monoagonists (e.g., semaglutide) in both diabetic and non-diabetic obese populations, with efficacy scaling with dose without compromising tolerability.
If you are treating obesity with medication, combining GIP and GLP-1 receptor activation (like tirzepatide) yields significantly more weight loss than activating only the GLP-1 receptor (like semaglutide). This combination does not increase the side effects that typically limit treatment, allowing for higher effective doses.
StrongSupportsVERY_HIGH confidence
Collectively, these data demonstrate that tirzepatide outperforms semaglutide in body weight endpoints without compromising its tolerability.
Why this rating
Supported by multiple phase III clinical trials (SURPASS, SURMOUNT) and large real-world data (n>41,000).
Source
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Aaron Novikoff et al. · Physiology · 2024
narrative_reviewCited 10×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →